吉西他滨联合顺铂、卡莫氟治疗晚期胰腺癌的疗效观察  

Observation of the efficacy of gemcitabine combined with cisplatin and carmofur in the treatment of advanced pancreatic carcinoma

作　　者：王翠[1] 宋雪[2] 仇恒志[2] 王淑贤[2] 

机构地区：[1]河北省承德医学院附属医院肿瘤外科,河北承德067000 [2]河北省承德医学院附属医院CT科,河北承德067000

出　　处：《中国医院药学杂志》2010年第11期947-948,共2页Chinese Journal of Hospital Pharmacy

摘　　要：目的:观察吉西他滨联合顺铂、卡莫氟治疗晚期胰腺癌的治疗效果。方法:选取经手术或病理学证实的胰腺癌患者73例。随机分成实验组(38例)用吉西他滨联合顺铂、卡莫氟治疗晚期胰腺癌4周,对照组(35例)用顺铂联合卡莫氟治疗晚期胰腺癌4周,比较两组的治疗效果和不良反应。结果:对照组部分缓解率为20.0%,半年生存率为57.1%,无1年以上生存者,疼痛改善率为40.0%;实验组部分缓解率为31.6%,半年及一年生存率分别为57.9%和26.3%,疼痛改善率为63.2%,两组比较均有统计学差异(P<0.05)。两组均有不同程度的骨髓抑制和胃肠道反应,其中骨髓抑制具有统计学差异(P<0.05)。结论:吉西他滨联合顺铂、卡莫氟治疗晚期胰腺癌患者可有效延长患者生命,改善生活质量,并无严重的不良反应。OBJECTIVE To observe the efficacy of gemeitabine combined with cisplatin and carmofur for the treatment of advanced pancreatic cancer. METHODS 73 cases of pancreatic cancer patients confirmed by surgery or pathology were choosen and randomly divide into experimental group （38 cases） and control group： the experimental group treated by gemeitabine, cisplatin and carmofur for four weeks, the control group （35 cases） treated by cisplatin and carmofur also for four weeks; the therapeutic effects and toxicity of the two groups were compared. RESULTS In control group, the partial remission rate（PR） was 20. 0%, the half-year survival rate was 57. 1% and no more than 1 year survival, pain improvement rate was 40. 0%; the experimental group＇s PR was 31.6%, the half-year survival rate and one-year survival rate were 57. 9% and 26. 3% respectively, and the pain improvement rate was 63.2%. There was a significant difference between the two groups （P〈0.05）. The two groups showed varying degrees of bone marrow suppression and gastrointestinal reactions, including bone marrow suppression with a significant difference （P〈0. 05）. CONCLUSION Gemcitabine combined with cisplatin and carmofur for advanced pancreatic cancer patients can effectively prolong life, improve the quality of life. There was no serious adverse drug reaction.

关 键 词：吉西他滨 顺铂 卡莫氟 晚期胰腺癌 不良反应 

分 类 号：R969[医药卫生—药理学]